Cargando…
Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B lymphocyte stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency for the...
Autores principales: | Guzman, Marla, Hui-Yuen, Joyce S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323799/ https://www.ncbi.nlm.nih.gov/pubmed/32612353 http://dx.doi.org/10.2147/DDDT.S216193 |
Ejemplares similares
-
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016) -
Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021) -
Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)